When Spirair co-founders Brandon McCutcheon, MD and James Kintzing, PhD, began developing SeptAlign™, they needed to find a material that could hold the nasal septum under tension during cartilage remodeling but also resorb within an appropriate time frame.

They shared how they identified the unmet need for a treatment option like SeptAlign, how they selected the material for SeptAlign, and what’s next for Spirair following SeptAlign’s FDA clearance. Read their contributed article in Medical Design & Outsourcing for more.

Spirair and its products may be featured by third-party publications. The opinions and comments expressed by a third party are their own. Spirair does not claim any accuracy of third-party reporting. Individual results may vary depending on the patient’s circumstances and condition.

MRK-022-A